Alibiflorin
(Synonyms: 芍药内酯苷) 目录号 : GN10298A monoterpene glycoside with diverse biological activities
Cas No.:39011-90-0
Sample solution is provided at 25 µL, 10mM.
Albiflorin is a major constituent contained in peony root; possesses therapeutic potential for neurodegenerative diseases.IC50 value:Target: in vitro: Albiflorin significantly ameliorated Glu-induced reduction of cell viability, nuclear and mitochondrial apoptotic alteration, reactive oxygen species accumulation, and B-cell lymphoma 2 (Bcl-2)/Bax ratio. Albiflorin also enhanced phosphorylation of AKT and its downstream element glycogen synthase kinase-3β, and this effect was abrogated by the AKT inhibitor LY294002 [1]. in vivo: Mice were exposed to X-ray radiation (400 Roentgen), and both mice and rabbits were intraperitoneally injected with cyclophosphamide (100.0 mg/kg) and cytarabine chloride (92.7 mg/kg), respectively, for 3 days to induce myelosuppression. Albiflorin was subsequently administrated intravenously at low (15.0 mg/kg for mice, 6.00 mg/kg for rabbits), intermediate (30.0 mg/kg for mice, 12.0 mg/kg for rabbits) and high (60.0 mg/kg for mice, 24.0 mg/kg for rabbits) doses, as well as orally (60.0 mg/kg for mice, 24.0 mg/kg for rabbits) for 7 days. Shenqi tablets were used as positive controls (oral administration of 936.0 mg/kg for mice, 336.0 mg/kg for rabbits). The administration of Albiflorin significantly ameliorated myelosuppression in all cases [2].
References:
[1]. Wang D, et al. Neuroprotective effects of paeoniflorin, but not the isomer albiflorin, are associated with the suppression of intracellular calcium and calcium/calmodulin protein kinase II in PC12 cells. J Mol Neurosci. 2013 Oct;51(2):581-90.
[2]. Xu W, et al. Therapeutic effects of combination of paeoniflorin and albiflorin from Paeonia radix on radiation and chemotherapy-induced myelosuppression in mice and rabbits. Asian Pac J Cancer Prev. 2011;12(8):2031-7.
Cas No. | 39011-90-0 | SDF | |
别名 | 芍药内酯苷 | ||
化学名 | ((1R,3R,4R,6S,9S)-4-hydroxy-6-methyl-8-oxo-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-7-oxatricyclo[4.3.0.03,9]nonan-9-yl)methyl benzoate | ||
Canonical SMILES | O=C1O[C@](C2([H])[H])(C([H])([H])[H])[C@@]3([C@@]1(C([H])([H])OC(C4=C([H])C([H])=C([H])C([H])=C4[H])=O)[C@@]([C@]2([H])O[H])([H])C3([H])[H])O[C@]([C@]([C@@]5([H])O[H])([H])O[H])([H])O[C@@](C([H])([H])O[H])([H])[C@@]5([H])O[H] | ||
分子式 | C23H28O11 | 分子量 | 480.46 |
溶解度 | ≥ 48mg/mL in DMSO | 储存条件 | Store at 2-8°C,protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0813 mL | 10.4067 mL | 20.8134 mL |
5 mM | 0.4163 mL | 2.0813 mL | 4.1627 mL |
10 mM | 0.2081 mL | 1.0407 mL | 2.0813 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet